Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mitizax · 1 trial · 3 indications
primary efficacy endpoint of D. Farinae specific IgG4 change from baseline to end of treatment
| Arm | Type | Description |
|---|---|---|
| Mitizax ALK HDM tablet | EXPERIMENTAL | Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU) |
| Placebo tablet | PLACEBO_COMPARATOR | Placebo tablet |
| Name | Type | Description |
|---|---|---|
| Mitizax | DRUG | Allergen extract |
| Placebo | DRUG | Placebo tablet |
Inclusion Criteria: * Written informed consent obtained before entering the study * Patients 18-65 years of age, with a clinical history consistent with HDM-induced allergic rhinitis or allergic rhinoconjunctivitis with or without HDM-induced allergic atopic asthma for more than 1 year * Use of sym...
Mitizax is an investigational small molecule being developed for the treatment of allergy, specifically for allergic rhinitis and atopic asthma induced by house dust mites. It is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.
Mitizax is being developed by Abbott Laboratories, a company traded on the stock exchange under the ticker symbol ABT. The drug is currently in Phase 3 clinical trials for allergy indications.
Mitizax is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still undergoing clinical trials to evaluate its safety and efficacy for treating allergies.
Mitizax has been studied in a Phase 3 clinical trial registered as NCT02596321. This completed trial investigated the immunologic effects and safety of a 60-day treatment in adults with house dust mite-induced allergic rhinitis and/or atopic asthma, enrolling 112 participants in Belarus and Russia.
Mitizax is a small molecule designed to treat allergies caused by house dust mites. It is being studied for its immunologic effects in patients with allergic rhinitis and atopic asthma, though the specific molecular target has not been disclosed.